| Company Name: |
J & K SCIENTIFIC LTD. |
| Tel: |
18210857532 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline
CAS:1432597-26-6
Package:50Mg,5Mg
|
| Company Name: |
Chembest Research Laboratories Limited |
| Tel: |
021-20908456 |
| Email: |
sales@BioChemBest.com |
| Products Intro: |
Product Name:5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
CAS:1432597-26-6
Purity:98% HPLC Package:5mg;10mg;50mg;100mg Remarks:Biochemical Reagents; Pharmaceutical Intermediates
|
| Company Name: |
Haoyuan Chemexpress Co., Ltd. |
| Tel: |
021-58950125 |
| Email: |
info@chemexpress.com |
| Products Intro: |
Product Name:LDN-212854
CAS:1432597-26-6
Purity:>98% Package:1020RMB/5mg
|
| Company Name: |
TOKYO CHEMICAL INDUSTRY CO., LTD. |
| Tel: |
03-36680489 |
| Email: |
Sales-JP@TCIchemicals.com |
| Products Intro: |
Product Name:LDN-212854 (This product is only available in Japan.)
CAS:1432597-26-6
Purity:95-98% Package:5 mg,25 mg
|
- LDN-212854
-
- $98.00
-
2026-07-27
- CAS:1432597-26-6
- Purity: 98.00%
- Supply Ability: 10g
- LDN212854
-
- $1.00
-
2019-12-23
- CAS:1432597-26-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| Product Name: | LDN212854 | | Synonyms: | LDN212854;Quinoline, 5-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-;BMP Inhibitor III;5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline;CS-1202;BMP INHIBITOR III;LDN212854;LDN 212854;5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline LDN 212854;LDN 212854 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | | CAS: | 1432597-26-6 | | MF: | C25H22N6 | | MW: | 406.48 | | EINECS: | 808-898-3 | | Product Categories: | Inhibitors | | Mol File: | 1432597-26-6.mol |  |
| | LDN212854 Chemical Properties |
| density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble1mg/mL, clear (warmed) | | form | powder | | pka | 8.79±0.10(Predicted) | | color | white to beige | | InChI | 1S/C25H22N6/c1-3-21(22-4-2-10-27-24(22)5-1)23-16-29-31-17-19(15-28-25(23)31)18-6-8-20(9-7-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2 | | InChIKey | BBDGBGOVJPEFBT-UHFFFAOYSA-N | | SMILES | [n]21ncc(c2ncc(c1)c5ccc(cc5)N6CCNCC6)c3c4c(nccc4)ccc3 | | CAS DataBase Reference | 1432597-26-6 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | LDN212854 Usage And Synthesis |
| Description | LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. | | In vitro | In myofibroblast C2C12 cells, LDN-212854 exhibits greater selectivity for BMP6-versus BMP4-induced osteogenic differentiation. | | In vivo | LDN-212854 (6 mg/kg, i.p.) effectively neutralize ALK2 signaling in vivo, and potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. | | Uses | 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline, contains the pyrazolo[1,5-a]pyrimidine scaffold, acting as a novel and selective bone morphogenetic protein receptor (BMP) inhibitors. It is a COVID19-related research product. | | Biological Activity | ldn-212854 is a selective inhibitor of bone morphogenetic protein (bmp) signaling with ic50 value of 1.2nm [1].in the kinase assay, ldn-212854 shows inhibitory activities against caalk2 and caalk5 with ic50 values of 16nm and 2μm, respectively. it demonstrates that ldn-212854 is selective against bmp over tgf-β signaling. besides that, the inhibition of caalk2 caused by ldn-212854 is 6- and 10-fold more potent than that of caalk1 and caalk3, respectively. in c2c12 cells transfected with bmp receptors, ldn-212854 also exerts preferential inhibition against caalk2. furthermore, in a transgenic alk2q207d model of heterotopic ossification, treatment of ldn-212854 prevents the formation of heterotopic bone and preserves limb range of motion [1]. | | Biochem/physiol Actions | LDN-212854 is also known as 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline. LDN-212854 prevents heterotopic ossification in an inducible mutant ALK2 (activin receptor-like kinase 2). | | in vivo | LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 4 weeks) potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva[1].
LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 10-14 days) suppresses HCC tumor progression through repression of ID1 in HCC xenografts model[2].
| Animal Model: | Murine inducible transgenic ALK2Q207D model of heterotopic ossification[1] | | Dosage: | 6 mg/kg | | Administration: | Intraperitoneal injection , twice daily for 4 weeks | | Result: | Prevented the formation of heterotopic bone and preserved limb range of motion with minimal or no impairment in the majority of mice. |
| Animal Model: | HCC xenografts (Huh7 or MT cell)[1] | | Dosage: | 6 mg/kg | | Administration: | Intraperitoneal injection, twice daily for 10-14 days. | | Result: | Inhibited tumor growth and showed less spheroid/colony formation ability than PBS-treated tumor cells. |
| | IC 50 | ACVR1: 1.3 nM (IC50); ALK1: 2.4 nM (IC50); BMPR1A: 85.8 nM (IC50); ALK4: 2133 nM (IC50); ALK5: 9276 nM (IC50) | | references | [1] mohedas a h, xing x, armstrong k a, et al. development of an alk2-biased bmp type i receptor kinase inhibitor. acs chemical biology, 2013, 8(6): 1291-1302. |
| | LDN212854 Preparation Products And Raw materials |
|